Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters

Obesity has been implicated in the etiology of postmenopausal breast cancer (PBC). We hypothesized that altered secretion of visfatin may underlie this association. We thus investigated the association of serum visfatin with PBC risk, taking into account known risk factors including adipokines and a...

Full description

Saved in:
Bibliographic Details
Published inMenopause (New York, N.Y.) Vol. 18; no. 11; p. 1198
Main Authors Dalamaga, Maria, Karmaniolas, Konstantinos, Papadavid, Evangelia, Pelekanos, Nicolaos, Sotiropoulos, George, Lekka, Antigoni
Format Journal Article
LanguageEnglish
Published United States 01.11.2011
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Obesity has been implicated in the etiology of postmenopausal breast cancer (PBC). We hypothesized that altered secretion of visfatin may underlie this association. We thus investigated the association of serum visfatin with PBC risk, taking into account known risk factors including adipokines and anthropometric and metabolic parameters. In a case-control study, we studied 102 postmenopausal women with pathologically confirmed, incident invasive breast cancer and 102 control women matched on age and time of diagnosis between 2003 and 2010 at Army Share Fund Hospital, Veterans' Hospital (NIMTS). Levels of serum visfatin, adiponectin, leptin, metabolic parameters, carcinoembryonic antigen, and CA 15-3 were determined. The mean serum visfatin level was significantly higher in case than in control participants (P < 0.001). Women in the highest quartile of visfatin concentration presented significantly higher odds for PBC, adjusting for age, date of diagnosis, education, body mass index, waist circumference, years with menstruation, parity/age at first full-term pregnancy, breast-feeding, family history of cancer, use of exogenous hormones, alcohol consumption, smoking status, homeostasis model assessment score, and serum leptin and adiponectin concentrations (odds ratio, 7.93; 95% CI, 2.52-24.9). In case participants, the visfatin level correlated significantly with the tumor marker CA 15-3 (P = 0.03) but not with metabolic and anthropometric variables (P > 0.05). Further prospective studies are needed to determine whether an elevated serum visfatin level is implicated in the etiopathogenesis of PBC or reflects changes during PBC progression and could therefore be used as a biomarker for PBC.
AbstractList Obesity has been implicated in the etiology of postmenopausal breast cancer (PBC). We hypothesized that altered secretion of visfatin may underlie this association. We thus investigated the association of serum visfatin with PBC risk, taking into account known risk factors including adipokines and anthropometric and metabolic parameters. In a case-control study, we studied 102 postmenopausal women with pathologically confirmed, incident invasive breast cancer and 102 control women matched on age and time of diagnosis between 2003 and 2010 at Army Share Fund Hospital, Veterans' Hospital (NIMTS). Levels of serum visfatin, adiponectin, leptin, metabolic parameters, carcinoembryonic antigen, and CA 15-3 were determined. The mean serum visfatin level was significantly higher in case than in control participants (P < 0.001). Women in the highest quartile of visfatin concentration presented significantly higher odds for PBC, adjusting for age, date of diagnosis, education, body mass index, waist circumference, years with menstruation, parity/age at first full-term pregnancy, breast-feeding, family history of cancer, use of exogenous hormones, alcohol consumption, smoking status, homeostasis model assessment score, and serum leptin and adiponectin concentrations (odds ratio, 7.93; 95% CI, 2.52-24.9). In case participants, the visfatin level correlated significantly with the tumor marker CA 15-3 (P = 0.03) but not with metabolic and anthropometric variables (P > 0.05). Further prospective studies are needed to determine whether an elevated serum visfatin level is implicated in the etiopathogenesis of PBC or reflects changes during PBC progression and could therefore be used as a biomarker for PBC.
Author Lekka, Antigoni
Papadavid, Evangelia
Dalamaga, Maria
Sotiropoulos, George
Pelekanos, Nicolaos
Karmaniolas, Konstantinos
Author_xml – sequence: 1
  givenname: Maria
  surname: Dalamaga
  fullname: Dalamaga, Maria
  email: madalamaga@med.uoa.gr
  organization: Department of Clinical Biochemistry, Medical School, University of Athens, Attikon General University Hospital, Athens, Greece. madalamaga@med.uoa.gr
– sequence: 2
  givenname: Konstantinos
  surname: Karmaniolas
  fullname: Karmaniolas, Konstantinos
– sequence: 3
  givenname: Evangelia
  surname: Papadavid
  fullname: Papadavid, Evangelia
– sequence: 4
  givenname: Nicolaos
  surname: Pelekanos
  fullname: Pelekanos, Nicolaos
– sequence: 5
  givenname: George
  surname: Sotiropoulos
  fullname: Sotiropoulos, George
– sequence: 6
  givenname: Antigoni
  surname: Lekka
  fullname: Lekka, Antigoni
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21712732$$D View this record in MEDLINE/PubMed
BookMark eNo1UMtOHDEQtCKiLAv5gwj5AxjwY7yzc4wQJEhIuSRn1Pa0WScztuX2Eu138kM4SzhUV1dLXa2uNTuJKSJjX6S4kmIcrp8WvBJWSI1abpVEJb35wE6l0aITeuhXbE30WwihRjV8YislB6kGrU7Zy-2Mz1Bx4oRlv_DnQB5qiNcxuNQYljAhz7tEDSXYRIe5qwUieSxAyNs6zsShIAei5MLR7G-oO14C_eHJ85yoLhhThj3BzG1BoModRIeFhzhhxlZinQ_cl7RwmEJu_7l2_rL55yNDnBrqrqScFqwluOOotWDT3FSGAk1hoXP20cNM-Pk_n7Ffd7c_b753Dz--3d98feicNsZ0XjsPTgyw3QorN97YEUU_2sGIUantZpj6XqNTZjRSTOO_wDZWSts37gVodcYu3nzz3i44PeYSFiiHx_d01SvEE4Uf
CitedBy_id crossref_primary_10_18632_oncotarget_15080
crossref_primary_10_1111_bcpt_12623
crossref_primary_10_1186_s12964_024_01474_4
crossref_primary_10_3109_09513590_2014_975687
crossref_primary_10_3892_or_2015_4391
crossref_primary_10_1111_ajco_12090
crossref_primary_10_1111_obr_12377
crossref_primary_10_1371_journal_pone_0067349
crossref_primary_10_3389_fcell_2024_1408844
crossref_primary_10_1007_s12020_018_1550_3
crossref_primary_10_1021_jm4001049
crossref_primary_10_1016_j_lfs_2022_120706
crossref_primary_10_1016_j_peptides_2017_04_007
crossref_primary_10_1210_er_2011_1015
crossref_primary_10_1515_hmbci_2018_0079
crossref_primary_10_1016_j_maturitas_2011_12_013
crossref_primary_10_1371_journal_pone_0073183
crossref_primary_10_1016_j_metabol_2018_01_001
crossref_primary_10_1002_cbf_3279
crossref_primary_10_1097_MD_0000000000011345
crossref_primary_10_1016_j_ejphar_2016_08_029
crossref_primary_10_2217_bmm_13_99
crossref_primary_10_1016_j_alkona_2015_05_002
crossref_primary_10_1016_j_tjog_2015_05_001
crossref_primary_10_1016_j_mehy_2012_07_036
crossref_primary_10_1158_1055_9965_EPI_13_0258
crossref_primary_10_5314_wjd_v2_i4_27
crossref_primary_10_18632_oncotarget_17853
crossref_primary_10_1016_j_bbrc_2012_01_072
crossref_primary_10_18632_oncotarget_8615
crossref_primary_10_18632_oncotarget_8932
crossref_primary_10_1016_j_cyto_2019_03_002
crossref_primary_10_1097_GME_0b013e31827f06dc
crossref_primary_10_6000_1929_2279_2015_04_01_3
crossref_primary_10_1016_j_lungcan_2018_10_010
crossref_primary_10_3390_biomedicines11020297
crossref_primary_10_1016_j_peptides_2013_11_010
crossref_primary_10_1016_j_canlet_2020_10_045
crossref_primary_10_1111_obr_13004
crossref_primary_10_1016_j_orcp_2015_08_017
crossref_primary_10_1111_bph_13505
crossref_primary_10_1016_j_jab_2014_08_003
crossref_primary_10_1186_1471_2407_13_54
crossref_primary_10_1007_s13679_019_00364_y
crossref_primary_10_1016_j_ygyno_2013_02_022
crossref_primary_10_3390_cancers15051572
crossref_primary_10_1158_1078_0432_CCR_15_2704
crossref_primary_10_1515_hmbci_2015_0016
crossref_primary_10_1016_j_metabol_2022_155326
crossref_primary_10_1097_MD_0000000000014359
crossref_primary_10_1515_hmbci_2015_0018
crossref_primary_10_3389_fendo_2020_00066
crossref_primary_10_1016_j_clinbiochem_2013_01_001
crossref_primary_10_1016_j_ejphar_2019_03_016
crossref_primary_10_3934_molsci_2017_3_252
crossref_primary_10_1016_j_semcancer_2024_01_003
crossref_primary_10_1016_j_phrs_2016_10_027
crossref_primary_10_1155_2015_253519
crossref_primary_10_4236_jdm_2022_122011
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1097/gme.0b013e31821e21f5
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1530-0374
ExternalDocumentID 21712732
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.GJ
.XZ
.Z2
0R~
123
4Q1
4Q2
4Q3
53G
5RE
5VS
AAAAV
AAHPQ
AAIQE
AAJCS
AAMTA
AARTV
AASCR
AAWTL
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABVCZ
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFS
ACILI
ACWDW
ACWRI
ACWUS
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEBDS
AEETU
AFDTB
AFEXH
AHQNM
AHVBC
AINUH
AJIOK
AJNWD
AJNYG
AJZMW
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BQLVK
BS7
C45
CGR
CS3
CUY
CVF
DIWNM
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
EX3
F5P
FCALG
FD6
FL-
GMYUL
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IN~
IPNFZ
JF9
JG8
JK3
JK8
K8S
KD2
L-C
NPM
N~M
O9-
OAG
OAH
OCUKA
ODA
ODMTH
OHYEH
OJAPA
OLG
OLW
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
PDI
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XXN
XYM
YFH
ZFV
ZZMQN
ID FETCH-LOGICAL-c3555-f3cfac07a880b16f5b9e049b750922867d443ec259510d912736b11b473640a32
IngestDate Sat Sep 28 07:48:36 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3555-f3cfac07a880b16f5b9e049b750922867d443ec259510d912736b11b473640a32
PMID 21712732
ParticipantIDs pubmed_primary_21712732
PublicationCentury 2000
PublicationDate 2011-Nov
PublicationDateYYYYMMDD 2011-11-01
PublicationDate_xml – month: 11
  year: 2011
  text: 2011-Nov
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Menopause (New York, N.Y.)
PublicationTitleAlternate Menopause
PublicationYear 2011
SSID ssj0002927
Score 2.3028412
Snippet Obesity has been implicated in the etiology of postmenopausal breast cancer (PBC). We hypothesized that altered secretion of visfatin may underlie this...
SourceID pubmed
SourceType Index Database
StartPage 1198
SubjectTerms Adiponectin - blood
Aged
Aged, 80 and over
Biomarkers - blood
Breast Neoplasms - blood
Breast Neoplasms - etiology
Carcinoembryonic Antigen - blood
Case-Control Studies
Cytokines - blood
Female
Humans
Leptin - blood
Logistic Models
Middle Aged
Mucin-1 - blood
Nicotinamide Phosphoribosyltransferase - blood
Obesity - blood
Obesity - complications
Odds Ratio
Postmenopause - blood
Risk
Title Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters
URI https://www.ncbi.nlm.nih.gov/pubmed/21712732
Volume 18
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Za9tAEMeXuIVSKKVN74uB9s1R45V1WI-lTQgtDnlIIG9hd7XbmuowkW1Iv2a_UGd2tZacOvR4sCwkIwnPT7szw39mGXunhcy0iXkwyVSMAcokCcRY4x6-eZFJUxlbNeH0ODk6iz6fx-c7g7c91dJyId-rH1vrSv7HqngM7UpVsv9g2fVF8QDuo31xixbG7V_Z-KDQK0EuI95tWQ5XVKdgmwIcVmhg3BPlLNfD-be6wc_lTNbNVREsrK-qL3H-GhakGWqGJP8SraG8Ht2Lzud1Q0p0DK6XDdpTkop9QWIxpUnK7lfRXRRXrlZF5LN5XdE4age0gmQzlReJinZdhpIW8nKdYnEXQaRe29SGvCR5TtN3maftvfW2hYN6iYxPAuEWLk88FU497eYSytpXM4zhLbNfnEeMD1Wv44kTdBlyUvfbqWFFBRdFd4ETnJq_i1aQaF8dUW-kS0ivt06XaD_EjwLqurN9Dlj6Oph2ROfcrZL921TjWhh_LXWXSw65DrmJ-z9HYOalxQ9jP46-Yvjns9cagPtTAzZIJzSUH1NCqnU2wixMfUVolu5vexzb79pd4lrsZH2o0wfsfhv8wAdH8kO2o6tddmfayjt22T2XRAZXG_eI_fSAgwUcPOD7fbzhZrzB4Q2IN3R4A-ENhDfUBjbxBoc3OLxhA28gvKGH9x44uPcAOYZNtO2hNdrQof2YnR0enH48CtpVSAKFvngcmLEyQo1SgTOd5ImJcXDDsFqSqx2GkyTNo2isVRhTrJJn9D8nknMZ4Xc0EuPwCbtV4XM9Y6BUbGKhQikwUEp5MuHC5FoYwUnLHann7Kkzz8XctZq58IZ7ceOZl-xuh_krdtvg2KZfo6O8kG8sKr8AaQjLbA
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elevated+serum+visfatin%2Fnicotinamide+phosphoribosyl-transferase+levels+are+associated+with+risk+of+postmenopausal+breast+cancer+independently+from+adiponectin%2C+leptin%2C+and+anthropometric+and+metabolic+parameters&rft.jtitle=Menopause+%28New+York%2C+N.Y.%29&rft.au=Dalamaga%2C+Maria&rft.au=Karmaniolas%2C+Konstantinos&rft.au=Papadavid%2C+Evangelia&rft.au=Pelekanos%2C+Nicolaos&rft.date=2011-11-01&rft.eissn=1530-0374&rft.volume=18&rft.issue=11&rft.spage=1198&rft_id=info:doi/10.1097%2Fgme.0b013e31821e21f5&rft_id=info%3Apmid%2F21712732&rft_id=info%3Apmid%2F21712732&rft.externalDocID=21712732